stockrow
Saturday 7 November 2026
Export GALT’s income statement to Excel — free account
Galectin Therapeutics Inc.
GALT Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- +63.1%
- Total debt
- −13.1%
Quarter to June 2026, against a year earlier
3.14
0.15
+5.02%
Follow GALT
Alert me
Galectin Therapeutics Inc. (GALT) P/E ratio
Galectin Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BNTC Benitec Biopharma Limited compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| EIKN Eikon Therapeutics, Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. | n/m |
| ALEC Alector, Inc. compare | 6.6× |
| AGEN Agenus Inc. compare | 10.7× |
| SCTX Scribe Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)